8-K: Theravance Biopharma Reports Q4 and Full Year 2023 Results, Achieves Non-GAAP Profitability

Theravance Biopharma achieved non-GAAP profitability in Q4 2023, driven by increased YUPELRI sales and effective expense management, while also advancing its ampreloxetine program.

Summary

• Theravance Biopharma announced its financial results for the fourth quarter and full year of 2023, highlighting a 9% year-over-year increase in YUPELRI net sales to $221 million.
• The company achieved non-GAAP profitability in Q4 2023 with a net profit of $1.4 million, compared to a GAAP net loss of $8.5 million.
• YUPELRI hospital volumes grew by 46% in 2023, exceeding internal targets and contributing significantly to overall net sales growth.
• The company completed a $325 million capital return program, reducing shares outstanding by 37%.
• The Phase 3 CYPRESS study for ampreloxetine is on track to enroll the last patient in the open-label portion by the second half of 2024.
• Theravance Biopharma expects to approach non-GAAP breakeven in the second half of 2024, with limited cash burn expected for the full year.
• The company is eligible for up to $200 million in milestone payments from Royalty Pharma based on TRELEGY sales, with the next $25 million milestone triggered at approximately $2.9 billion in 2024 sales.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth for YUPELRI, achievement of non-GAAP profitability, and progress in the ampreloxetine program. The company's financial position is also solid, and the potential for milestone payments adds to the positive sentiment. However, the GAAP net loss and the expected non-GAAP loss in the first half of 2024 temper the overall sentiment slightly.

Positives

• YUPELRI sales are growing, with a 9% increase in net sales year-over-year and a 4% increase quarter-over-quarter.
• The company achieved non-GAAP profitability in Q4 2023, indicating improved financial performance.
• Hospital volumes for YUPELRI are increasing significantly, demonstrating strong market penetration.
• The company has completed a substantial capital return program, returning value to shareholders.
• The ampreloxetine program is progressing, with the Phase 3 CYPRESS study on track.
• The company has a strong cash position of $102.4 million as of December 31, 2023.
• The company is eligible for significant milestone payments from TRELEGY sales.

Negatives

• The company reported a GAAP net loss of $8.5 million in Q4 2023, although this was offset by non-GAAP profitability.
• The company expects a non-GAAP loss in the first half of 2024, although they anticipate approaching breakeven in the second half.
• The company's total revenue for Q4 2023 was $17.6 million, which is primarily from Viatris collaboration revenue.

Risks

• The company's future profitability is subject to risks related to factors that could increase cash requirements or expenses.
• There are risks associated with the success of clinical studies and regulatory approvals for product candidates.
• The company is dependent on third parties for conducting clinical studies and commercializing products.
• The company faces risks related to protecting and enforcing its intellectual property rights.
• The company's share price is subject to volatility and fluctuations based on market conditions.

Future Outlook

The company expects to approach non-GAAP breakeven in the second half of 2024, with limited cash burn expected for the full year. They also anticipate continued growth in YUPELRI sales and are advancing the ampreloxetine program. The company is eligible for up to $200 million in milestone payments from Royalty Pharma based on TRELEGY sales.

Management Comments

• Rick E Winningham, Chief Executive Officer, stated that the Theravance team delivered a strong performance in 2023, having achieved financial objectives in the fourth quarter and exceeded the annual goal for YUPELRI hospital growth.
• The CEO also mentioned they look forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of this year.
• The company is excited to host a virtual investor event in the second quarter to review the science underpinning their expectation that ampreloxetine can provide clinical benefits in MSA patients with nOH.

Industry Context

This announcement reflects the ongoing efforts of pharmaceutical companies to develop and commercialize treatments for respiratory and neurological conditions. The growth in YUPELRI sales indicates a positive trend in the COPD market, while the progress of ampreloxetine highlights the focus on rare diseases like MSA. The company's collaboration with Viatris and the potential milestone payments from Royalty Pharma are also indicative of common industry practices.

Comparison to Industry Standards

• Theravance Biopharma's YUPELRI is a once-daily nebulized LAMA for COPD, competing with other long-acting bronchodilators like Boehringer Ingelheim's Spiriva (tiotropium) and GlaxoSmithKline's Anoro (umeclidinium/vilanterol), though these are primarily delivered via inhalers.
• The 46% growth in YUPELRI hospital volumes is a strong performance compared to the overall market, suggesting effective market penetration and adoption in the hospital setting.
• The company's focus on ampreloxetine for MSA-related nOH positions it in a niche market with limited competition, as current treatments like droxidopa (Northera) have limitations and are not specifically indicated for MSA.
• The potential $200 million in milestone payments from TRELEGY sales is a significant opportunity, comparable to other royalty and milestone agreements in the pharmaceutical industry, such as those between Royalty Pharma and various biotech companies.
• The company's non-GAAP profitability in Q4 2023 is a positive sign, as many biotech companies often operate at a loss during development phases, and achieving profitability is a key milestone for investors.

Legal Proceedings

• Settlement agreements were reached with Teva, Accord, and Orbicular regarding patent litigation for YUPELRI, granting them licenses to market generic versions starting April 23, 2039.
• Patent litigation against four other ANDA filers remains pending.

Stakeholder Impact

• Shareholders benefit from the completed capital return program and the potential for future milestone payments.
• Employees are part of a company that is achieving financial goals and advancing its pipeline.
• Patients with COPD benefit from the availability of YUPELRI, and those with MSA may benefit from ampreloxetine in the future.
• Viatris is a key partner in the commercialization of YUPELRI, and their collaboration is essential for the company's success.

Next Steps

• The company plans to continue growing YUPELRI net sales in 2024.
• They will complete enrollment in the CYPRESS study in the second half of 2024.
• A virtual investor event is planned for the second quarter of 2024 to discuss ampreloxetine.
• The company will advance regulatory and early commercial preparedness throughout 2024.
• They plan to file for approval of YUPELRI in China in mid-2024.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, Ampreloxetine, COPD, MSA, Non-GAAP Profitability, Financial Results, Clinical Trials, Milestone Payments, TRELEGY